Trismus and diffuse polymyalgia: An unusual presentation of recurrent metastatic ovarian cancer

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Benjamin, Ramsis ^a   Zhai, Jing ^a   Morgan, Robert ^a   Prakash, Neal ^a  

^a Department of Neurology City of Hope ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; HYDROCODONE; NARCOTIC AGENT; OXYCODONE; TRASTUZUMAB;

ADULT; ALLODYNIA; ARTICLE; BILIARY TRACT DRAINAGE; CANCER GROWTH; CANCER RECURRENCE; CARCINOMATOUS MENINGITIS; CASE REPORT; CLINICAL FEATURE; COLLOID CARCINOMA; DENERVATION; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; HYPERALGESIA; JAW MOVEMENT; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MONONEUROPATHY; MUCOSA INFLAMMATION; NAIL DISEASE; NECK PAIN; NEEDLE BIOPSY; OBSTRUCTIVE JAUNDICE; ONYCHOMADESIS; OVARY CANCER; OVARY METASTASIS; PANCREAS METASTASIS; PARANEOPLASTIC SYNDROME; PERIPHERAL NEUROPATHY; POLYMYOSITIS; POLYRADICULITIS; PRIORITY JOURNAL; SHOULDER PAIN; TRISMUS; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEDGE RESECTION; WHOLE BODY IMAGING;

EID: 84900798086     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-203361     Document Type: Article

References (26)

1. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. Atlanta, GA: Department of Health and Human Services, Center for Disease Control and Prevention, and National Cancer Institute, 2013. http://www.cdc.gov/uscs
2. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004;22:1040-4. (Pubitemid 41095036)
3. Vereczkey I, Serester O, Dobos J, et al. Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors. Pathol Oncol Res 2011;17:551 -9.
4. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90:378-81. (Pubitemid 36952030)
5. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1and BRCA2 carriers. Clin Cancer Res 2004;10:2473-81. (Pubitemid 38445709)
6. McGuire V, Jesser CA, Whittemore AS. Survival among US women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399-403. (Pubitemid 34211865)
7. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005;97:519-23. (Pubitemid 40614898)
8. Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratifi ed treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013;229:111-20.
9. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4. (Pubitemid 38018236)
10. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel- based chemotherapy, the GINECO experience. Ann Oncol 2010;21:2377-81.
11. Karabuk E, Faruk Kose M, Hizli D, et al. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study. J Gynecol Oncol 2013;24:160 -6.
12. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005;97:436-41. (Pubitemid 40614887)
13. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-82. (Pubitemid 32108089)
14. Papadia A, Morotti M. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature. Arch Gynecol Obstet 2013;287:733-41.
15. Jain A, Ryan PD, Seiden MV. Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location. J Natl Compr Canc Netw 2012;10:1076-80.
16. Sher-Ahmed A, Buscerna J, Sardi A. A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy. Gynecol Oncol 2002;86:91-4. (Pubitemid 34757057)
17. Sasaki H, Ohara N, Minamikawa T, et al. Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci 2008;54:E174-82.
18. Hynninen J, Auranen A, Carpen O, et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol 2012;126:64-8.
19. Thompson EW, Newgreen DF. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005;65:5991-5. (Pubitemid 40994377)
20. Zhang Y, Tang H, Zhang T, et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011;303:47 -55.
21. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991;9:543-51.
22. Gabriel B, Mildenberger S, Weisser CW, et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004;24:921-7. (Pubitemid 38625040)
23. Chen H, Wang L, Beretov J, et al. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 2010;27:557-69.
24. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-71.
25. Fujiwara M, Taube J, Sharma M, et al. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. J Cutan Pathol 2010;37:938-43.
26. Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol 2012;19:140-51.